In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.
about
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials GroupHaemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997)Intravenous azithromycin.A comparative In vitro surveillance study of gemifloxacin activities against 2,632 recent Streptococcus pneumoniae isolates from across Europe, North America, and South America. The Gemifloxacin Surveillance Study Research GroupReview and comparison of advanced-generation macrolides clarithromycin and dirithromycin.Evaluation of the Dade MicroScan MICroSTREP antimicrobial susceptibility testing panel with selected Streptococcus pneumoniae challenge strains and recent clinical isolates.Extremely high prevalence of nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among children in Kaohsiung, Taiwan.Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agentsAntipneumococcal activities of a ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin).Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997.Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE lociSusceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance studyComparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.A review of clinical trials with fluoroquinolones with an emphasis on new agents.Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States.Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance studyIn vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogensIn vitro activities of cefotaxime, ceftriaxone, ceftazidime, cefpirome, and penicillin against Streptococcus pneumoniae isolatesActivities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study.Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologiesComparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci.MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptibleCanadian national survey of prevalence of antimicrobial resistance among clinical isolates of Streptococcus pneumoniae. Canadian Bacterial Surveillance Network.Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study.MIC and time-kill studies of antipneumococcal activity of GV 118819X (sanfetrinem) compared with those of other agentsTrovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae.Susceptibilities of 228 penicillin- and erythromycin-susceptible and -resistant pneumococci to RU 64004, a new ketolide, compared with susceptibilities to 16 other agents.Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.Postantibiotic effect of sanfetrinem compared with those of six other agents against 12 penicillin-susceptible and -resistant pneumococci.Lung infections. 2. Branhamella catarrhalis: epidemiological and clinical aspects of a human respiratory tract pathogen.Global fluoroquinolone resistance epidemiology and implictions for clinical use.Methods for predicting susceptibility of Streptococcus pneumoniae to cefiximeSurrogate disks for predicting cefotaxime and ceftriaxone susceptibilities of Streptococcus pneumoniaeInterpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group.Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98.Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep.Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.Effects of various test media on the activities of 21 antimicrobial agents against Haemophilus influenzae.
P2860
Q28344357-6C7A5929-A923-4817-862B-A51A64842E55Q30453668-D944D614-1C99-4955-AA36-3AD211D43948Q33543121-E13AEAE1-5BD4-49BB-9E07-84669B587CDAQ33593962-7D9AF62F-7CA4-4AAE-AC02-8C2FD6C3DE7EQ33598839-84EC9989-4D88-4AA2-B544-10AA266322BBQ33659832-1C553275-E8FA-4E6A-8921-4D9D71567E30Q33672446-F778B3AD-CBCF-426F-BACE-7101C5DB43A4Q33691239-6543A874-64B8-4346-9CF4-8E441C3462ABQ33692938-87FAF99A-F654-491C-88E5-93E65407B4BCQ33704215-B3A5B248-9780-422A-900D-79C135B24533Q33976055-A8D5388B-49B4-4574-B0E0-C02F6BDAA725Q33977347-54878104-32CC-4A73-985D-E03B8D5F03AAQ33981554-425165D0-B13B-4251-BA25-861BD88BB7D0Q34074724-35BAF50F-6CD0-4440-A36E-51B365489EC7Q34347889-7D9C3331-DACC-4E74-B175-A0CACF5119B8Q34437719-BD8DD595-2B82-45C9-81D2-880C08B59674Q34737818-37CA0A26-CEB4-45D9-8460-3F20E6BDFAA6Q35111191-ABE547AF-8DCE-4D52-90B2-74BF4286DC49Q35119197-C75E82D7-BF08-49C9-A582-3F1D7583528FQ35122591-F4DB6B1B-A6DA-4960-9612-107A7A908D30Q35124415-FF2B5C5D-16C0-48F2-9B71-FBBBB73C0CF3Q35125580-631965E2-C19A-4112-8CBE-428B87A460A4Q35126352-5AC85609-B274-4001-A4A5-D54FD77B5B4EQ35126660-5D740C3E-EA63-4BCB-877D-B5C78BAE5739Q35127137-0AB98D68-1781-46BA-89F0-A88820BFA48AQ35130432-629A4952-DB15-40F1-A808-9D11EAFBF32DQ35131455-AB904E02-4226-438D-8D1A-C0F529C88EA0Q35133005-FC43E3B5-F3E6-4494-A4F2-C221D13F11A1Q35135982-33BA22D0-C453-4CF2-9B4A-C9DE7D730D4AQ35137932-22A90943-629C-44F2-9886-AEDD71A4BB0DQ35138485-5CDEFE8B-B409-406F-9192-1B6CE6263984Q35563934-AED4CF54-56CE-4C82-9817-4D098076C804Q36337074-8C441E16-0B86-4135-AD66-E435DF3ADD0AQ36521261-55D14FAA-8111-4002-9297-DA2D584E1A53Q36540874-30C09C9D-2466-4E02-A1DE-1BB92DD1A186Q36542543-071AF727-382E-41C7-87C4-92A0E9F31A1DQ37093776-42F53CAD-B41A-41BB-9516-F03118604789Q37334391-EB021402-EB82-4CDB-BB3F-4A8F05F114C4Q37998398-F219C22E-D14F-464B-BD88-5E36243319DEQ39664823-43A037C5-D983-4BF0-9789-370331214138
P2860
In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.
description
1994 nî lūn-bûn
@nan
1994 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
In vitro activities of 12 oral ...... ical Centers in 1992 and 1993.
@ast
In vitro activities of 12 oral ...... ical Centers in 1992 and 1993.
@en
type
label
In vitro activities of 12 oral ...... ical Centers in 1992 and 1993.
@ast
In vitro activities of 12 oral ...... ical Centers in 1992 and 1993.
@en
prefLabel
In vitro activities of 12 oral ...... ical Centers in 1992 and 1993.
@ast
In vitro activities of 12 oral ...... ical Centers in 1992 and 1993.
@en
P2093
P2860
P356
P1476
In vitro activities of 12 oral ...... ical Centers in 1992 and 1993.
@en
P2093
P2860
P304
P356
10.1128/AAC.38.10.2419
P407
P577
1994-10-01T00:00:00Z